Former FDA Leaders Push Back Against Recent Changes at the Agency
Written by Emily J. Thompson, Senior Investment Analyst
Source: Barron's
- FDA Leadership Announcement: The FDA announced that Dr. Richard Pazdur, a respected leader with a long tenure, will head the agency's drug review division.
- Sign of Normalcy: This appointment is perceived as a positive indication that the FDA is returning to normal operations.
Analyst Views on XBI
Wall Street analysts forecast XBI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XBI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 128.180
Low
Averages
High
Current: 128.180
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
